## **Kluwer Patent Blog**

## Hospira v. Novartis, Court of Appeal of England and Wales, 19 December 2013 "

Amy Cullen (Bristows) · Thursday, March 27th, 2014

The Court of Appeal upheld the judgment of the High Court (Arnold J) that claims concerning treatment of osteoporosis with zoledronic acid were not entitled to an earlier priority date and were therefore invalid over an intervening publication. The Court held that the disclosure in the priority document was either too general or too specific, and therefore did not support a claim to the use of zoledronic acid administered intravenously about once a year to treat osteoporosis with a dose of 2-10mg.

The full summary of this case has been published on Kluwer IP Law.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

## Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?


Learn how Kluwer IP Law can support you.

1

79% of the lawyers think that the importance of legal technology will increase for next year.

**Drive change with Kluwer IP Law.** The master resource for Intellectual Property rights and registration.





2022 SURVEY REPORT The Wolters Kluwer Future Ready Lawyer Leading change

This entry was posted on Thursday, March 27th, 2014 at 1:00 pm and is filed under Case Law, Priority right, United Kingdom, Validity

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.